Fast In-House Next-Generation Sequencing in the Diagnosis of Metastatic Non-small Cell Lung Cancer: A Hospital Budget Impact Analysis

被引:0
|
作者
Silas, Ubong [1 ]
Blueher, Maximilian [1 ]
Smith, Antonia Bosworth [1 ]
Saunders, Rhodri [1 ]
机构
[1] Coreva Sci GmbH & Co KG, Konigswinter, Germany
来源
关键词
targeted therapy; turnaround time; health economic analysis; hospital costs; genetic testing; return on investment;
D O I
10.36469/jheor.2023.77686
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: Targeted therapy for cancer is becoming more frequent as the understanding of the molecular pathogenesis increases. Molecular testing must be done to use targeted therapy. Unfortunately, the testing turnaround time can delay the initiation of targeted therapy. Objective: To investigate the impact of a next-generation sequencing (NGS) machine in the hospital that would allow for in-house NGS testing of metastatic non-small cell lung cancer (mNSCLC) in a US setting. Methods: The differences between 2 hospital pathways were established with a cohort-level decision tree that feeds into a Markov model. A pathway that used in-house NGS (75%) and the use of external laboratories (so-called send-out NGS) (25%), was compared with the standard of exclusively send-out NGS. The model was from the perspective of a US hospital over a 5-year time horizon. All cost input data were in or inflated to 2021 USD. Scenario analysis was done on key variables. Results: In a hospital with 500 mNSCLC patients, the implementation of in-house NGS was estimated to increase the testing costs and the revenue of the hospital. The model predicted a $710 060 increase in testing costs, a $1 732 506 increase in revenue, and a $1 022 446 return on investment over 5 years. The payback period was 15 months with in-house NGS. The number of patients on targeted therapy increased by 3.38%, and the average turnaround time decreased by 10 days when in-house NGS was used. Discussion: Reducing testing turnaround time is a benefit of in-house NGS. It could contribute to fewer mNSCLC patients lost to second opinion and an increased number of patients on targeted therapy. The model outcomes predicted that, over a 5-year period, there would be a positive return on investment for a US hospital. The model reflects a proposed scenario. The heterogeneity of hospital inputs and the cost of send-out NGS means context-specific inputs are needed. Conclusion: Using in-house NGS testing could reduce the testing turnaround time and increase the number of patients on targeted therapy. Additional benefits for the hospital are that fewer patients will be lost to second opinion and that in-house NGS could generate additional revenue.
引用
收藏
页码:111 / 118
页数:8
相关论文
共 50 条
  • [31] Mutational profile of non-small cell lung cancer by targeted next-generation sequencing in the Mexican population
    Socca, Giovanny
    Alaez, Carmen
    Hernandez-Pedro, Norma
    Barrios-Bernal, Pedro A.
    Carrillo-Sanchez, Karol
    Aviles, Alejandro
    Arrieta, Oscar
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S24 - S25
  • [32] Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer
    Pisapia, Pasquale
    Pepe, Francesco
    Iaccarino, Antonino
    Sgariglia, Roberta
    Nacchio, Mariantonia
    Conticelli, Floriana
    Salatiello, Maria
    Tufano, Rossella
    Russo, Gianluca
    Gragnano, Gianluca
    Girolami, Ilaria
    Eccher, Albino
    Malapelle, Umberto
    Troncone, Giancarlo
    FRONTIERS IN MEDICINE, 2021, 8
  • [33] Next Generation Sequencing in Non-Small Cell Lung Cancer: Pitfalls and Opportunities
    Lazzari, Chiara
    Bulotta, Alessandra
    Cangi, Maria Giulia
    Bucci, Gabriele
    Pecciarini, Lorenza
    Bonfiglio, Silvia
    Lorusso, Vincenza
    Ippati, Stefania
    Arrigoni, Gianluigi
    Grassini, Greta
    Doglioni, Claudio
    Gregorc, Vanesa
    DIAGNOSTICS, 2020, 10 (12)
  • [34] Next generation sequencing of brain metastasis in non-small cell lung cancer
    Thibodeau, Bryan
    Cardenas, Paola Yumpo
    Ahmed, Samreen
    Dunn, Marc
    Johnson, Matthew
    Wilson, George
    CANCER RESEARCH, 2016, 76
  • [35] Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspective
    de Alava, Enrique
    Pareja, Maria Jesus
    Carcedo, David
    Arrabal, Natalia
    Garcia, Jose-Francisco
    Bernabe-Caro, Reyes
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (06) : 1033 - 1042
  • [36] Next-generation sequencing of non-small cell lung cancer using a customized, targeted sequencing panel: Emphasis on small biopsy and cytology
    DiBardino, David M.
    Rawson, David W.
    Saqi, Anjali
    Heymann, Jonas J.
    Pagan, Carlos A.
    Bulman, William A.
    CYTOJOURNAL, 2017, 13
  • [37] Evaluation of the Mutation Profile via Next-Generation Sequencing in a Turkish Population with Non-small Cell Lung Cancer
    Cetin, Nesibe Kahraman
    Erdogdu, Ibrahim Halil
    Bozkurt, Emin
    Meteoglu, Ibrahim
    BALKAN MEDICAL JOURNAL, 2021, 38 (06) : 382 - 391
  • [38] Secondary myelodysplastic syndromes identified via next-generation sequencing in a non-small cell lung cancer patient
    Feng, Yongzhi
    Chen, Xialin
    Jiang, Keran
    Zhang, Ding
    Tao, Feng
    Ni, Dan
    Zhang, Jun
    Wu, Lixin
    Cai, Jinping
    Jiang, Libin
    Yu, GenHua
    Shi, Lin
    BMC MEDICAL GENOMICS, 2021, 14 (01)
  • [39] A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: a case report
    Xiaoyi Xu
    Haoyi Wang
    Zhaonan Yu
    Xianguo Chen
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 1825 - 1827
  • [40] Identification of MET gene amplifications using next-generation sequencing in non-small cell lung cancer patients
    Clave, S.
    Salido, M.
    Rocha, P.
    Hardy-Werbin, M.
    Gibert, J.
    Riera, X.
    Weingartner, E.
    Cerqueira, G.
    Nichol, D.
    Simmons, J.
    Taus, A.
    Pijuan, L.
    Bellosillo, B.
    Arriola, E.
    ANNALS OF ONCOLOGY, 2019, 30